Soluble BCMA was detectable in peripheral blood by a simple and inexpensive assay in all patients, even in non‐secretory disease or during BCMA‐targeted therapies, and significant changes in its levels were observed over time. The gene discussed is TNFRSF17; the disease is glycogen storage disease VI.